Cogent Biosciences (COGT) 8-K Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 StudyATTCK-17-01 at the 2018 ASH Annual Meeting

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 1, 2018

UNUM THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware	001-38443	46-5308248
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
200 Cambridge Park Drive, Suite 3100 Cambridge, Massachusetts		02140
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (617)945-5576

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant toRule 14a-12 under the Exchange Act (17 CFR240.14a-12)

☐ Pre-commencement communications pursuant toRule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

☐ Pre-commencement communications pursuant toRule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule12b-2 of the Securities Exchange Act of 1934.

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

Item 7.01 Regulation FD Disclosure.

On December 1, 2018, Unum Therapeutics Inc. (the “Company”) issued a press release titled “Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 StudyATTCK-17-01 at the 2018 ASH Annual Meeting.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form8-K.

In addition, on December 2, 2018, the Company issued a press release titled “Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 StudyATTCK-20-03 at the 2018 ASH Annual Meeting.” A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form8-K.

The information in Item 7.01 of this Current Report on Form8-K, including Exhibits 99.1 and 99.2, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Exhibit No.	Description
99.1	Press release issued by Unum Therapeutics Inc. on December 1, 2018.
99.2	Press release issued by Unum Therapeutics Inc. on December 2, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 3, 2018	UNUM THERAPEUTICS INC.
	By:	/s/ Charles Wilson
		Charles Wilson, Ph.D.
		Chief Executive Officer